Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00840086 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00840086 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 150 participants.
The verdict
NCT00840086, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding episodes during surgical procedures.
Interventions
- DRUG turoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00840086
The ClinicalTrials.gov registry entry for NCT00840086 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which turoctocog alfa is the first listed.
NCT00840086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00840086 about?
NCT00840086 is a clinical study titled "Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects". This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial investigates safety and e...
What is the current status of trial NCT00840086?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2009-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00840086?
The interventions under investigation include: turoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT00840086?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.